If you were facing imminent death and the government ruled out your trying an experimental drug, you'd be angry that federal regulations pursued you to the very end of life. The Goldwater is fighting to change this:

The Goldwater Institute has been the driving force in the Right To Try movement, which seeks to allow dying patients with no other options to access investigational medicines. The Right to Try has already become law in 24 states with bipartisan support. But some opposition remains. The primary argument against the Right To Try is the U.S. Food and Drug Administration already has an effective alternative for dying patients called Expanded Access, more commonly known as compassionate use.

Now, a new investigation by the Goldwater Institute shows that terminally ill patients rarely have the opportunity to even apply for compassionate use. The complicated and time-consuming process strongly discourages doctors and researchers from working with patients to try treatments that might save their lives. Each year, only about 1,200 terminally ill patients in America will even be able to submit an application for compassionate use. This year, nearly 600,000 Americans will die of cancer alone.

Goldwater President Darcy Olsen testified on the Right to Try before Congress last week.